Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 10/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674720 | 0.80 | PIK3CA (0.47) | FLT3MTORPIK3CAPIK3CG | |
| SCHEMBL366206 | 0.76 | MTOR (0.43) | MTORSTAT3PIK3CAPIK3CGCNR2 | |
| SCHEMBL364128 | 0.75 | MAPK1 (0.36) | MTOR | |
| SCHEMBL799171 | 0.74 | MTOR (0.39) | FLT3MTORPIK3CAPIK3CGYTHDC1 | |
| Bicarbonate SCHEMBL362971 | 0.74 | FLT3 (0.39) | FLT3MTORPIK3CAPIK3CGYTHDC1 | |
| Bicarbonate SCHEMBL13674719 | 0.74 | FLT3 (0.41) | FLT3MTORSTAT3PIK3CAPIK3CG | |
| SCHEMBL13673773 | 0.73 | FLT3 (0.47) | FLT3MTORSTAT3PIK3CAPIK3CG | |
| SCHEMBL363672 | 0.71 | MTOR (0.43) | MTORSTAT3PIK3CAPIK3CGCNR2 | |
| SCHEMBL799262 | 0.71 | PIK3CA (0.50) | FLT3MTORPIK3CAPIK3CGYTHDC1 | |
| SCHEMBL364150 | 0.70 | PIK3CA (0.43) | MTORSTAT3PIK3CAPIK3CGCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | FLT3 2698/4885MTOR 1/4885STAT3 304/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | FLT3 2698/4885MTOR 1/4885STAT3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.